Lacassagne’s biological resource centre was set up in March 2005 in response to INCa’s 2004 tender in collaboration with the University Hospital of Nice and is an integral part of the Commonal Hospital Tumor Biobank. This THC is governed by a partnership agreement between the CHU and Lacassagne formalizing a mode of operation superimposed through strategic committees, steering and scientific advice. This translates into a joint activity report with the INCa and a unique display on the Virtual Tumor Biobank website of the Cancéropôle PACA.

The THC is managed jointly by the two institutions under the responsibility of Professor HOFMAN (Laboratory of Clinical and Experimental Pathology, University Hospital Center of NICE). Dr. PEYROTTES (Pathology Anatomy Unit, Antoine Lacassagne Center) is Deputy Head.

The Biological Resource Center collects frozen and / or paraffinized tumor samples, plasma and sera, and has a DNA library.
Its purpose is to facilitate clinical research by any project developer. It is thus part of a regional and national research dynamic in total coherence with the research programs of the two structures and also respects INCa’s recommendations regarding cryopreservation for health purposes.

This bank is not dissociated from collection of biological tumor samples necessary for diagnoses and therapeutic follow-up.

The staff of the CRB is qualified to carry out the management of biological tissue products and their exploitation and receives training on management of infectious risks, handling of the material proper to cryopreservation and analysis of sample quality.

The staff is under the responsibility of Dr. Birtwisle Peyrottes


The managers of the Tumor Biobank are committed to ensuring its proper functioning, including ensuring the establishment and sustainability of an optimal level of safety for samples frozen and stored in the THC.

A quality policy is put in place at each stage of tissue management. The cryopreservation of tumor tissues must indeed meet standardized criteria from collection to storage to ensure the quality of tumor samples whose characteristics can be studied later, correlating them with the clinical history of tumor patients. The organization of the circuits between the different actors is of fundamental importance for the quality of the Tumor Biobank.

The essential points of this quality policy are:

  • organization of dissemination of information documents to patients relating to the existence, organization and missions of the Tumor Biobank, a form allowing patients to express their agreement or disagreement on the use, for research purposes, of biological samples taken from their operational residues;
  • sensitization of surgeons to the importance of sampling conditions and the time lapse between the onset of ischemia and the freezing of samples;
  • confirmation of the diagnosis from the surgical specimen by an anatomical pathologist: selection of tissue fragments of the lesions to cryopreserve, including a healthy zone in parallel, if possible;
  • identification of samples by a unique tissue number;
  • RNA extraction and RNA quality verification on bioanalyzer: 5% of samples and at random;
  • the traceability of the cold chain implemented by a procedure guaranteeing the maintenance and verification of temperature and the action to be taken in the event of failure
  • computer archiving of clinical, anatomo-pathological, frozen tissue, RNA quality data.